Disease Modifying Effect Of Bhallatakadi Churna In Amavata(Rheumatoid Arthritis)
Phase 3
- Conditions
- Health Condition 1: M059- Rheumatoid arthritis with rheumatoid factor, unspecified
- Registration Number
- CTRI/2023/10/058251
- Lead Sponsor
- Dr Amey Abhay Watwe
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
1.Subjects having classical signs and symptoms of Amavata and Rheumatoid arthritis(American College of Rheumatology).
3. On-going NSAID’s will be continued.
4. RA TITRE more than 20 IU/ml.
5. CRP more than 3mg/L.
6. Patients willing to give consent.
Exclusion Criteria
1. Subject who are under Disease Modifying Anti Rheumatic Drug and Long actingSteroids.
2. Patients who underwent Panchakarma Line of treatment for 2weeks or more at the timeof interrogation.
3. Pregnant and Lactating women.
4. Patient with co-morbidity which is life threatening or interferes with the intervention
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Validation of Bhallatakadi Churna as DMARD and its effect on symptoms of Amavata, RA Titre, CRP and ESR.Timepoint: 15Day,30day,45day
- Secondary Outcome Measures
Name Time Method Safety of trial drug and Adverse drug reaction <br/ ><br>Aggravation of Symptoms of Amavata(RA)Timepoint: 15day, 30 day, 45 day